Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab. Boltz A, Radunsky K, Weingessel B, Vecsei-Marlovits VP, et al. Graefes Arch Clin Exp Ophthalmol 2022 Mar 29. pii: 10.1007/s00417-022-05634.

Read + Share

Amedeo Smart

Independent Medical Education

Boltz A, Radunsky K, Weingessel B, Vecsei-Marlovits VP, et al. Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab. Graefes Arch Clin Exp Ophthalmol 2022 Mar 29. pii: 10.1007/s00417-022-05634.
PMID: 35348844